Trial · NCT04850261
Injection Free IVF
NCT04850261, Phase 2, Withdrawn, Insel Gruppe AG, University Hospital Bern
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Injection Free IVF. Trials, record NCT04850261. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04850261
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Injection Free IVF
- NCT number
- NCT04850261
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Conditions
- Fertility Disorders
- Interventions
- hCG Injection, Nafarelin nasal spray
- First posted
- 2021-04-20
- Last updated
- 2024-10-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment tolerability | It will be assessed between Ovulation induction and follicle aspiration. It takes about 3 minutes to complete in the questionnaire | Treatment tolerability will be measured with the Treatment tolerability subscale of the Fertility Quality of Life (FertiQoL) Treatment questionnaire. The subscale assesses the experience of mental and physical symptoms and disruption in daily life due to treatment. It consists of 4 items. Each item has a set of 5 possible responses, from which patients have to chose the one that most closely reflects how they think and feel. |
| Primary | Discomfort of treatment | It will be assessed between Ovulation induction and follicle aspiration. It takes about 2 minutes to complete in the questionnaire | The level of discomfort of the treatment encountered by the patients will be measured with 3 Visual Analogue Scale (VAS) questions ranging from 1 - 10 to specifically compare the discomfort imposed by the two treatments. |
| Secondary | Embryo transfer rate | It will be documented after the embryo transfer (2-5 days after follicle aspiration) | Number of embryos transferred in the two groups |
| Other | Oocyte collection rate | It will be reported by the IVF-laboratory 2-5 days after the follicle aspiration | Oocyte collection rate |
| Other | Number of mature Oocytes | It will be reported by the IVF-laboratory 2-5 days after the follicle aspiration | Number of mature Oocytes |
| Other | Fertilisation rate per aspirated oocyte | It will be reported by the IVF-laboratory 2-5 days after follicle aspiration | Fertilisation rate per aspirated oocyte |
| Other | Estradiol concentration 10 ±1 day after follicle aspiration | Blood withdrawal (5 min.) 9-11 days after follicle aspiration | 9-11 days after the follicle aspiration, venous blood will be drawn in order to determine Estradiol concentration in serum |
| Other | Progesterone concentration 10 ±1 day after follicle aspiration | Blood withdrawal (5 min.) 9-11 days after follicle aspiration | 9-11 days after the follicle aspiration, venous blood will be drawn in order to determine Progesterone concentration in serum |
| Other | Clinical pregnancy rate per initiated cycle | Pregnancy test 14-21 days after follicle aspiration | Clinical pregnancy rate (positive pregnancy test 14-21 days after the follicle aspiration) per initiated cycle |
| Other | Duration of luteal phase | 14-21 days after follicle aspiration, if pregnancy test ist negative | If the pregnancy test 14-21 days after the follicle aspiration is negative, we will inquire and document the length of the luteal phase |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04850261
GET https://conductscience.org/api/trials/v1/NCT04850261/registered